Developer docs
API playgroundTry for free, no card

Search company profiles

Roche Products Ltd, UK

Full company profile

uuid000klmm

Namestring
Roche Products Ltd, UK
Legal namestring
Roche Products Limited
Websiteurl
roche.co.uk
Company typeenum
Public
Founded yearint
1896
Descriptiontext

Roche Products Ltd UK is the UK operating subsidiary of F. Hoffmann-La Roche Ltd, a Swiss-headquartered global healthcare group listed on the SIX Swiss Exchange (ticker: RO). Established in the UK in 1908, the company combines pharmaceutical and diagnostics capabilities under a unified entity structure that includes Roche Products Limited (pharmaceuticals, headquartered at Welwyn Garden City), Roche Diagnostics Limited, and Roche Diabetes Care Limited (both operating from a National Distribution Centre in Burgess Hill, West Sussex). The UK business employs over 2,000 people across more than 50 nationalities and serves NHS trusts, healthcare professionals, patients, and patient organisations as its primary customer base.

The product portfolio spans pharmaceutical medicines for oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions, and rare indications (including haemophilia and spinal muscular atrophy), alongside in vitro diagnostic tests and instruments ranging from bedside devices to large hospital laboratory systems, diabetes care products under the Accu-Chek and CoaguChek sub-brands, and AI-enabled digital diagnostic solutions. Notable technology components include NLP-powered genomic data extraction (the Genomic Information Finder, developed with GOSH DRIVE), computer-vision-based pathology interpretation, and clinical decision-support algorithms. In July 2024, the diagnostics entity expanded its point-of-care capabilities through the acquisition of LumiraDx UK Ltd and related entities.

Revenue is generated through three principal streams: pharmaceutical sales via NHS prescription channels, hardware sales of diagnostic instruments and reagents to NHS hospitals and laboratories, and recurring digital health and subscription solutions. The go-to-market is enterprise field sales with deep NHS collaborative working partnerships. Pricing is not publicly disclosed. The company is ABPI-compliant, holds five ISO certifications (27001, 9001, 14001, 45001, 22301), and operates under NHS framework agreements as the dominant UK market channel.

Short descriptiontext

Roche Products Ltd UK is the UK subsidiary of Swiss pharmaceutical and diagnostics group F. Hoffmann-La Roche Ltd, combining pharmaceutical medicines, in vitro diagnostic tests and instruments, AI-enabled digital diagnostics, and diabetes care products, serving NHS trusts, healthcare professionals, patients, and patient organisations across the UK and Ireland.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersWelwyn Garden City, United Kingdom
HQ citystring
Welwyn Garden City
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical medicines, in vitro diagnostics, diagnostic instruments, digital health solutions, clinical diagnostics
Industry4 codes
1Oncology Specialty Pharmaceuticals
CodeHLAIACAAPrimaryYes
2Immunology & Autoimmune Specialty Pharmaceuticals
CodeHLAIACABPrimaryNo
3Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryNo
4Neurology & Psychiatry (CNS) Pharmaceuticals
CodeHLAIAAAFPrimaryNo
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical and Diagnostic Products
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical products
TypeOthers
Description

Development and sale of innovative medicines for oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions, and rare indications. Revenue generated through NHS prescriptions and direct sales.

roche.co.uk
2Diagnostic tests and instruments
TypeHardware Sales
Description

Sale of in vitro diagnostic tests, instruments and analysers to NHS hospitals, laboratories and healthcare providers. Instruments range from small bedside devices to large laboratory systems.

roche.co.uk
3Digital health solutions
TypeSubscription Recurring
Description

Digital solutions supporting specialists in diagnostic work including AI-powered diagnostic interpretation tools and clinical decision support systems.

roche.co.uk
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Accu-Chek
Description

Blood glucose monitoring systems, diabetes management apps, and insulin delivery systems for patients with diabetes.

roche.co.uk
+1 more record
Core offering1 text field

Roche Products Ltd UK develops, manufactures and supplies innovative pharmaceutical medicines for serious diseases in oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions and rare indications, alongside in vitro diagnostic tests, diagnostic instruments (from bedside to high-throughput laboratory systems), and AI-powered digital health solutions. Products are sold primarily to the NHS, hospital laboratories and healthcare professionals across the UK and Ireland, supported by field-based technical teams and a National Distribution Centre in Burgess Hill.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduction in systolic blood pressure by 5 mm Hg reduces risk of major cardiovascular events by about 10%
+4 more records
Product overview1 text field

Roche Products Ltd UK operates as a unified pharmaceutical and diagnostics company combining pharmaceuticals and diagnostics capabilities. The core product portfolio includes pharmaceutical medicines (treatments for oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions, and rare indications) and diagnostic solutions (in vitro tests, diagnostic instruments, and digital health solutions). These are complemented by diabetes care products under the Accu-Chek and CoaguChek sub-brands, and the AI-powered Genomic Information Finder for genomic data extraction. The company also provides grants to support patient organisations and maintains an electronic medicines compendium for UK prescribing information. Roche UK is part of the broader Roche Group which includes Roche Diagnostics Limited, Roche Diabetes Care Limited, and LumiraDx UK Limited (acquired July 2024).

Product and service1 record
1Pharmaceutical Medicines
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Roche's partnership with GOSH DRIVE developed the Genomic Information Finder (GIF), an AI-powered tool using Natural Language Processing to automate extraction of key genomic insights from reports. Extracts data in hours rather than months, potentially transforming how genomic data is accessed and used for research and patient care.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive partnership to develop Roche UK's Social Value strategy. Priorities centred around social mobility, healthy community, and healthy planet. Using Social Value Portal's online platform to measure, manage and maximise contribution to UK society. Target of £200 million social value by end of 2026.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-promotion agreement in place between Roche Products Ltd and Chugai Pharma UK Ltd. Both companies independently disclose their contributions in accordance with ABPI requirements.

Strategic tierMinorTypeOthers
Description

Roche Products Ltd is a member of ABPI. Members are governed by Code of Conduct ensuring professional work with integrity, transparency about engagement with others.

Strategic tierMinorTypeOthers
Description

Roche UK is a member of ABHI for diagnostics. Trade body membership ensures adherence to professional codes of conduct beyond legal requirements.

Strategic tierMinorTypeOthers
Description

Roche Products Ltd is a member of EMG, working with trade body on improving patient access to innovative medicines and supporting NHS to deliver high-quality care.

7Confederation of British Industries (CBI)
Strategic tierMinorTypeOthers
Description

Roche Products Ltd is a member of CBI. Plays active role in key issues including improving patient access to innovative medicines and supporting wider life science sector in UK.

roche.co.uk
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple collaborative working projects with NHS trusts including: The Christie NHS Trust (programme management), Great Ormond Street Hospital (clinical informatics), Bradford Teaching Hospitals (retinal screening), Newcastle Hospitals (AI diagnostics), various breast cancer projects, MS HES dashboard, and influenza pathway optimisation. Projects span MDT approaches, clinical trials, AI diagnostics, and pathway development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK pharmaceutical subsidiary of AstraZeneca, one of the largest pharma companies in the UK with major oncology, cardiovascular, and respiratory franchises and deep NHS partnerships — directly comparable to Roche UK in scale, therapeutic focus, and NHS go-to-market model.

TypeDirect peer
Description

UK operations of Swiss-headquartered Novartis, with overlapping portfolios in oncology, ophthalmology, and rare diseases (including MS therapies). Direct competitor for NHS contracts, ABPI membership, and access to the same NHS formulary and NICE pathways.

TypeDirect peer
Description

UK subsidiary of US-headquartered Pfizer, with broad pharma portfolio across oncology, vaccines, inflammation/immunology, and rare disease — competing head-to-head with Roche UK in oncology and increasingly in personalised healthcare approaches.

TypeDirect peer
Description

UK-headquartered global pharma with major UK R&D and commercial operations across respiratory, HIV, oncology, and vaccines — directly comparable in NHS partnership model, ABPI membership, and diversified pharma-distribution footprint.

TypeDirect peer
Description

UK subsidiary of Merck & Co. with strong oncology (Keytruda-led) and vaccines franchises, plus a mature NHS engagement model — competes directly with Roche UK across multiple oncology indications and NHS pathway collaborations.

TypeDirect peer
Description

UK operations of Sanofi with broad pharma and vaccines portfolio, including immunology (Dupixent) and rare disease units — comparable scale and similar NHS enterprise sales motion to Roche UK.

TypeDirect peer
Description

UK subsidiary of Eli Lilly competing in oncology, diabetes (relevant to Roche Diabetes Care), immunology, and rare diseases — significant UK commercial presence and NHS engagement comparable to Roche UK.

TypeDirect peer
Description

UK subsidiary operating Bayer's pharma division (cardiovascular, women's health, oncology) and radiology business — comparable in offering a combined pharma-and-diagnostics commercial model in the UK, including point-of-care imaging presence.

TypeDirect peer
Description

UK operations of Abbott span diagnostics (core lab, point-of-care, rapid diagnostics) and diabetes care (FreeStyle Libre), directly overlapping with Roche Diagnostics Limited and Roche Diabetes Care Limited — closest direct competitor in the diagnostics + diabetes care segments in the UK.

TypeEmerging player
Description

UK presence of Siemens Healthineers focused on in-vitro diagnostics, lab automation, and digital health for hospital systems — competing with Roche Diagnostics Limited for NHS laboratory contracts and digital pathology deployments, although with a narrower specialty pharma footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Roche Products Ltd, UK

Pharmaceutical and Diagnostic Productsroche.co.uk

Roche Products Ltd UK is the UK subsidiary of Swiss pharmaceutical and diagnostics group F. Hoffmann-La Roche Ltd, combining pharmaceutical medicines, in vitro diagnostic tests and instruments, AI-enabled digital diagnostics, and diabetes care products, serving NHS trusts, healthcare professionals, patients, and patient organisations across the UK and Ireland.

What Roche Products Ltd, UK does

Roche Products Ltd UK is the UK operating subsidiary of F. Hoffmann-La Roche Ltd, a Swiss-headquartered global healthcare group listed on the SIX Swiss Exchange (ticker: RO). Established in the UK in 1908, the company combines pharmaceutical and diagnostics capabilities under a unified entity structure that includes Roche Products Limited (pharmaceuticals, headquartered at Welwyn Garden City), Roche Diagnostics Limited, and Roche Diabetes Care Limited (both operating from a National Distribution Centre in Burgess Hill, West Sussex). The UK business employs over 2,000 people across more than 50 nationalities and serves NHS trusts, healthcare professionals, patients, and patient organisations as its primary customer base.

The product portfolio spans pharmaceutical medicines for oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions, and rare indications (including haemophilia and spinal muscular atrophy), alongside in vitro diagnostic tests and instruments ranging from bedside devices to large hospital laboratory systems, diabetes care products under the Accu-Chek and CoaguChek sub-brands, and AI-enabled digital diagnostic solutions. Notable technology components include NLP-powered genomic data extraction (the Genomic Information Finder, developed with GOSH DRIVE), computer-vision-based pathology interpretation, and clinical decision-support algorithms. In July 2024, the diagnostics entity expanded its point-of-care capabilities through the acquisition of LumiraDx UK Ltd and related entities.

Revenue is generated through three principal streams: pharmaceutical sales via NHS prescription channels, hardware sales of diagnostic instruments and reagents to NHS hospitals and laboratories, and recurring digital health and subscription solutions. The go-to-market is enterprise field sales with deep NHS collaborative working partnerships. Pricing is not publicly disclosed. The company is ABPI-compliant, holds five ISO certifications (27001, 9001, 14001, 45001, 22301), and operates under NHS framework agreements as the dominant UK market channel.

Roche Products Ltd, UK firmographics

Firmographics
Name
Roche Products Ltd, UK
Legal name
Roche Products Limited
Website
https://roche.co.uk
Company type
Public
Founded year
1896
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Roche Products Ltd UK is the UK subsidiary of Swiss pharmaceutical and diagnostics group F. Hoffmann-La Roche Ltd, combining pharmaceutical medicines, in vitro diagnostic tests and instruments, AI-enabled digital diagnostics, and diabetes care products, serving NHS trusts, healthcare professionals, patients, and patient organisations across the UK and Ireland.
Ownership category
akta.pro rank

Roche Products Ltd, UK industry classification

Industry
Product category
Pharmaceutical and Diagnostic Products
NAICS
Pharmaceutical and Medicine Manufacturing (32541), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro primary industry
Oncology Specialty Pharmaceuticals (HLAIACAA)
akta.pro secondary industries
Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

  • Pharmaceutical medicines
  • In vitro diagnostics
  • Diagnostic instruments
  • Digital health solutions
  • Clinical diagnostics

Where Roche Products Ltd, UK is headquartered

Location

Headquarters

HQ city
Welwyn Garden City
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Roche Products Ltd, UK business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical products: Development and sale of innovative medicines for oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions, and rare indications. Revenue generated through NHS prescriptions and direct sales.
  2. Diagnostic tests and instruments: Sale of in vitro diagnostic tests, instruments and analysers to NHS hospitals, laboratories and healthcare providers. Instruments range from small bedside devices to large laboratory systems.
  3. Digital health solutions: Digital solutions supporting specialists in diagnostic work including AI-powered diagnostic interpretation tools and clinical decision support systems.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Roche Products Ltd, UK product offering

Product offering

Core offering

Roche Products Ltd UK develops, manufactures and supplies innovative pharmaceutical medicines for serious diseases in oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions and rare indications, alongside in vitro diagnostic tests, diagnostic instruments (from bedside to high-throughput laboratory systems), and AI-powered digital health solutions. Products are sold primarily to the NHS, hospital laboratories and healthcare professionals across the UK and Ireland, supported by field-based technical teams and a National Distribution Centre in Burgess Hill.

Product overview

Roche Products Ltd UK operates as a unified pharmaceutical and diagnostics company combining pharmaceuticals and diagnostics capabilities. The core product portfolio includes pharmaceutical medicines (treatments for oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions, and rare indications) and diagnostic solutions (in vitro tests, diagnostic instruments, and digital health solutions). These are complemented by diabetes care products under the Accu-Chek and CoaguChek sub-brands, and the AI-powered Genomic Information Finder for genomic data extraction. The company also provides grants to support patient organisations and maintains an electronic medicines compendium for UK prescribing information. Roche UK is part of the broader Roche Group which includes Roche Diagnostics Limited, Roche Diabetes Care Limited, and LumiraDx UK Limited (acquired July 2024).

Differentiator

Problem solved

Functional benefit

Brands

  • Accu-Chek: Blood glucose monitoring systems, diabetes management apps, and insulin delivery systems for patients with diabetes.
  • CoaguChek

Products and services

  • Pharmaceutical Medicines

Quantifiable outcome

  • Reduction in systolic blood pressure by 5 mm Hg reduces risk of major cardiovascular events by about 10%
  • +4 more outcomes

Companies that use Roche Products Ltd, UK

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Roche Products Ltd, UK technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Roche Products Ltd, UK partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Great Ormond Street Hospital NHS Trust (GOSH DRIVE)coreStrategic or Co-development PartnerRoche's partnership with GOSH DRIVE developed the Genomic Information Finder (GIF), an AI-powered tool using Natural Language Processing to automate extraction of key genomic insights from reports. Extracts data in hours rather than months, potentially transforming how genomic data is accessed and used for research and patient care.
  • Social Value PortalcoreStrategic or Co-development PartnerExclusive partnership to develop Roche UK's Social Value strategy. Priorities centred around social mobility, healthy community, and healthy planet. Using Social Value Portal's online platform to measure, manage and maximise contribution to UK society. Target of £200 million social value by end of 2026.
  • Chugai Pharma UK LtdcoreStrategic or Co-development PartnerCo-promotion agreement in place between Roche Products Ltd and Chugai Pharma UK Ltd. Both companies independently disclose their contributions in accordance with ABPI requirements.
  • Association of British Pharmaceutical Industries (ABPI)minorOthersRoche Products Ltd is a member of ABPI. Members are governed by Code of Conduct ensuring professional work with integrity, transparency about engagement with others.
  • Association of British HealthTech Industries (ABHI)minorOthersRoche UK is a member of ABHI for diagnostics. Trade body membership ensures adherence to professional codes of conduct beyond legal requirements.
  • European Medicines Group (EMG)minorOthersRoche Products Ltd is a member of EMG, working with trade body on improving patient access to innovative medicines and supporting NHS to deliver high-quality care.
  • Confederation of British Industries (CBI)minorOthersRoche Products Ltd is a member of CBI. Plays active role in key issues including improving patient access to innovative medicines and supporting wider life science sector in UK.
  • NHS Trusts (Multiple)coreStrategic or Co-development PartnerMultiple collaborative working projects with NHS trusts including: The Christie NHS Trust (programme management), Great Ormond Street Hospital (clinical informatics), Bradford Teaching Hospitals (retinal screening), Newcastle Hospitals (AI diagnostics), various breast cancer projects, MS HES dashboard, and influenza pathway optimisation. Projects span MDT approaches, clinical trials, AI diagnostics, and pathway development.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Roche Products Ltd, UK competitors and assessment

Company assessment

Direct peers

  • AstraZeneca UK: UK pharmaceutical subsidiary of AstraZeneca, one of the largest pharma companies in the UK with major oncology, cardiovascular, and respiratory franchises and deep NHS partnerships — directly comparable to Roche UK in scale, therapeutic focus, and NHS go-to-market model.
  • Novartis UK: UK operations of Swiss-headquartered Novartis, with overlapping portfolios in oncology, ophthalmology, and rare diseases (including MS therapies). Direct competitor for NHS contracts, ABPI membership, and access to the same NHS formulary and NICE pathways.
  • Pfizer UK: UK subsidiary of US-headquartered Pfizer, with broad pharma portfolio across oncology, vaccines, inflammation/immunology, and rare disease — competing head-to-head with Roche UK in oncology and increasingly in personalised healthcare approaches.
  • GSK UK: UK-headquartered global pharma with major UK R&D and commercial operations across respiratory, HIV, oncology, and vaccines — directly comparable in NHS partnership model, ABPI membership, and diversified pharma-distribution footprint.
  • Merck Sharp & Dohme (MSD) UK: UK subsidiary of Merck & Co. with strong oncology (Keytruda-led) and vaccines franchises, plus a mature NHS engagement model — competes directly with Roche UK across multiple oncology indications and NHS pathway collaborations.
  • Sanofi UK: UK operations of Sanofi with broad pharma and vaccines portfolio, including immunology (Dupixent) and rare disease units — comparable scale and similar NHS enterprise sales motion to Roche UK.
  • Eli Lilly UK: UK subsidiary of Eli Lilly competing in oncology, diabetes (relevant to Roche Diabetes Care), immunology, and rare diseases — significant UK commercial presence and NHS engagement comparable to Roche UK.
  • Bayer UK: UK subsidiary operating Bayer's pharma division (cardiovascular, women's health, oncology) and radiology business — comparable in offering a combined pharma-and-diagnostics commercial model in the UK, including point-of-care imaging presence.
  • Abbott UK (Diagnostics + Diabetes Care): UK operations of Abbott span diagnostics (core lab, point-of-care, rapid diagnostics) and diabetes care (FreeStyle Libre), directly overlapping with Roche Diagnostics Limited and Roche Diabetes Care Limited — closest direct competitor in the diagnostics + diabetes care segments in the UK.

Emerging players

  • Siemens Healthineers UK: UK presence of Siemens Healthineers focused on in-vitro diagnostics, lab automation, and digital health for hospital systems — competing with Roche Diagnostics Limited for NHS laboratory contracts and digital pathology deployments, although with a narrower specialty pharma footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Roche Products Ltd, UK social profiles

Digital presence

Roche Products Ltd, UK compliance and trust

Trust signal

Compliance6 records

Roche Products Ltd, UK financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Roche Products Ltd, UK leadership team

Management profile

Number of profiles

Profiles3 records

Roche Products Ltd, UK subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Roche Products Ltd, UK funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Roche Products Ltd, UK M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Products Ltd, UK

What does Roche Products Ltd, UK do?

Roche Products Ltd UK develops, manufactures and supplies innovative pharmaceutical medicines for serious diseases in oncology, immunology, ophthalmology, multiple sclerosis, neuromuscular conditions and rare indications, alongside in vitro diagnostic tests, diagnostic instruments (from bedside to high-throughput laboratory systems), and AI-powered digital health solutions. Products are sold primarily to the NHS, hospital laboratories and healthcare professionals across the UK and Ireland, supported by field-based technical teams and a National Distribution Centre in Burgess Hill.

Is Roche Products Ltd, UK a public or private company?

Roche Products Ltd, UK is a public company. It is classified as corporate owned and is currently operating.

When was Roche Products Ltd, UK founded?

Roche Products Ltd, UK was founded in 1896. It employs 1,001 to 5,000 people.

Where is Roche Products Ltd, UK based?

Roche Products Ltd, UK is headquartered in Welwyn Garden City, United Kingdom, in the Europe region.

How does Roche Products Ltd, UK make money?

Three revenue lines are on record. Pharmaceutical products are the primary driver. The others are diagnostic tests and instruments and digital health solutions.

Who are Roche Products Ltd, UK's main competitors?

Direct peers on record are AstraZeneca UK, Novartis UK, Pfizer UK, GSK UK, Merck Sharp & Dohme (MSD) UK, Sanofi UK, Eli Lilly UK, Bayer UK and Abbott UK (Diagnostics + Diabetes Care). Siemens Healthineers UK is listed as an emerging player.

Does Roche Products Ltd, UK have an API?

No public API is recorded for Roche Products Ltd, UK.

What industry is Roche Products Ltd, UK in?

Roche Products Ltd, UK's product category is Pharmaceutical and Diagnostic Products. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Punch NewspapersLagos Signs Blood Screening Deal for Safer TransfusionsThe Lagos State Government signed a five-year concession agreement with approved private concessionaires to standardize blood screening across public hospitals, replacing a previous arrangement that expired in June 2023. Roche Products Limited will supply fully automated blood screening systems compliant with WHO requirements through a reagent rental model, while the government retains regulatory oversight throughout the concession period. The initiative aims to strengthen detection of transfusion-transmissible infections including HIV, Hepatitis B, Hepatitis C, and syphilis, and address documented weaknesses such as inconsistent equipment, discordant test results, and inadequate traceability in the state's blood transfusion system.WikipediaGriffin Place: Difference between revisionsGriffin Place in Welwyn Garden City, England, originally built in 1938 as the Roche Products Factory headquarters, was designed by Swiss architect Otto Rudolf Salvisberg and was named 'Building of the Year' by The Architects' Journal in January 1939. The pharmaceutical facility, operated by Roche Products Limited (a subsidiary of Swiss company Hoffmann-La Roche), was later expanded in the post-war period and eventually vacated by Roche in 2005 after employing hundreds of workers. The historic complex was converted into 34 apartments completed in 2019, preserving its modernist architectural features.EIN PresswireKFSHRC and Roche Products Sign Framework Agreement to Secure Uninterrupted Supply of Critical High-Value MedicationsKing Faisal Specialist Hospital and Research Centre (KFSHRC) and Roche Products signed a long-term framework agreement at the Global Health Exhibition 2025 to guarantee stable and uninterrupted supply of critical, high-value medications essential to patient care. The agreement provides fixed pricing for high-cost medications, mitigating stock-out risks for oncology and advanced care therapies while enabling predictable budgeting and financial sustainability aligned with Saudi Vision 2030. The strategic supply arrangement supports KFSHRC's mission to deliver specialized healthcare by ensuring access to innovative therapies through a resilient partnership.SciencedirectOvercoming data management challenges in oncology research: Lessons from an NHS, industry, technology start-up and academic collaborationThe CUP-COMP study, a multi-site UK oncology trial, successfully implemented a secure data lake architecture to manage large-scale genomic and clinical data from cancer patients. The project involved collaboration between The Christie NHS Foundation Trust, Roche Products Ltd, and technology start-up Concr, utilizing Amazon Web Services for storage. This approach enabled compliant, federated data sharing and analysis across diverse stakeholders, providing a scalable template for future precision oncology research.PrwebRoche UK Deploys LifeLink Chatbot as Next Generation Medical Information Desk Virtual AssistantLifeLink announced the successful deployment of its AMII chatbot technology at Roche UK to serve as a virtual medical information desk. The system provides 24/7 responses to inquiries from healthcare professionals regarding product characteristics and from patients about information leaflets.